Can a physician predict the clinical response to first-line immunomodulatory treatment in relapsing–remitting multiple sclerosis?

BACKGROUND: Decreased relapse rate and slower disease progression have been reported with long-term use of immunomodulatory treatments (IMTs, interferon beta or glatiramer acetate) in relapsing–remitting multiple sclerosis. There are, however, patients who do not respond to such treatments, and they...

Descripción completa

Detalles Bibliográficos
Autores principales: Mezei, Zsolt, Bereczki, Daniel, Racz, Lilla, Csiba, Laszlo, Csepany, Tünde
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2012
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3484901/
https://www.ncbi.nlm.nih.gov/pubmed/23118540
http://dx.doi.org/10.2147/NDT.S36771

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3484901/
https://www.ncbi.nlm.nih.gov/pubmed/23118540
http://dx.doi.org/10.2147/NDT.S36771

Ejemplares similares